Abstract:siRNA therapy offers immense potential for clinical application. Under physiological conditions, however, siRNA was demonstrated to have a short half-life. Additionally, it may also cause ubiquitous gene silencing as it does not possess a tissue-specific homing mechanism. Thus, the rate-limiting step in the emergence of siRNA as a potential therapeutic agent is the current lack of a safe and tissue- or cell-specific in vivo delivery system. Herein, we propose a novel, cell-specific method for the in vivo delivery of siRNA to dendritic cells (DCs) with the purpose of inducing immune modulation. CD40 siRNA was incorporated within the interior of 86 nm liposomes, which were decorated with surface-bound mAb NLDC-145 as a targeting mechanism. The siRNA encapsulation efficiency was determined to be approximately 7%. CD40 siRNA immunoliposomes (CD40 siILs) were able to specifically bind to DCs and silence CD40 expression in vitro. Furthermore, in vitro CD40-silenced DCs significantly inhibited the proliferation of alloreactive T cells in an MLR. Upon in vivo administration, siIL-encapsulated, Cy3-labeled siRNA exhibited moderate uptake by the liver at an early time point following administration with greater accumulation in the spleen at a later time point. In contrast, naked siRNA primarily accumulated in the kidney immediately after administration and circulated out in a short time period. To address in vivo gene silencing and immune modulation, mice were simultaneously immunized with KLH and subcutaneously injected with DC-specific CD40 siILs, siILs containing negative control siRNA, naked CD40 siRNA, or PBS. A second injection of CD40 siILs, or control treatments, followed 24 h later. Flow cytometry, reverse transcriptase PCR, and quantitative real-time PCR analysis of CD11c(+) DCs from mice treated with CD40 siILs demonstrated reduced expression of CD40, in comparison with control groups. CD11c(-) cells were also analyzed by flow cytometry, but no differences were observed between treatment groups. Furthermore, CD40 siIL-treated mice were found to have an increased proportion of Treg cells (CD4(+)CD25(+) FoxP3(+)), and DCs cells from these mice were able to inhibit T cell proliferation in an antigen-specific recall response. In summary, CD40 siILs were shown to specifically target and deliver CD40 siRNA to DCs, significantly reducing CD40 expression and resulting in DC-mediated immune modulation as well as generation of Treg cells. These findings highlight the therapeutic potential for siRNA-based and DC-mediated immunotherapy in the clinic. To the best of our knowledge, this is the first study to use siILs for targeted delivery of siRNA to DCs and for immune modulation.

Immune modulation through silencing CD80 and CD86 in dendritic cells using siRNA

Immune Modulation Through Silencing CD80 and CD86 in Dendritic Cells Using Sirna (88.4)

Silencing CD40 in dendritic cells by siRNA

Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA.

Immune Modulation And Tolerance Induction By Relb-Silenced Dendritic Cells Through Rna Interference

Sirna Specific Delivery System for Targeting Dendritic Cells.

Effect of silencing CD86 expression on antigen presenting cells by siRNA on activation of T lymphocytes

A Novel In Vivo Sirna Delivery System Specifically Targeting Dendritic Cells And Silencing Cd40 Genes For Immunomodulation

Silencing of CD86 in dendritic cells by small interfering RNA regulates cytokine production in T cells from patients with allergic rhinitis in vitro.

A Novel in Vivo Sirna Delivery Technology for Dendritic Cell-Specific Gene Silencing and Immune Modulation (89.5)

Effects of Silencing of Rel-A Gene Expression by RNA Interference on the Dendritic Cells

MyD88 Knockdown by Liposome-mediated RNA Interference to Porcine Monocyte-derived Dendritic Cell

silencing CD 40 genes for immunomodulation siRNA delivery system specifically targeting dendritic cellsin vivoA novel

RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis

Preventing Immune Rejection Through Gene Silencing.

Silencing Invariant Chain of Dcs Enhances Th1 Response Using Small Interfering Rna

Novel Therapy for Allergy Through Immunomodulation by CD40-silenced Dendritic Cells

Integrin CD11b Negatively Regulates TLR9-triggered Dendritic Cell Cross-Priming by Upregulating Microrna-146A.

Inhibition of Allergic Responses by CD40 Gene Silencing

RNASilencing of CD40 Using Small Interfering Novel Vaccination for Allergy through Gene

Silenced suppressor of cytokine signaling 1 (SOCS1) enhances the maturation and antifungal immunity of dendritic cells in response to Candida albicans in vitro